Engineering yeast to produce fraxetin from ferulic acid and lignin

被引:0
作者
He, Bo-Tao [1 ,2 ,3 ]
Li, Bing-Zhi [1 ,2 ,3 ]
机构
[1] Tianjin Univ, Frontiers Sci Ctr Synthet Biol, Tianjin 300072, Peoples R China
[2] Tianjin Univ, Sch Chem Engn & Technol, Key Lab Syst Bioengn, Minist Educ, Tianjin, Peoples R China
[3] Tianjin Univ, Frontiers Res Inst Synthet Biol, Tianjin, Peoples R China
关键词
Fraxetin; Ferulic acid; Lignin; Synthetic biology; BIOSYNTHESIS; INTEGRATION; GENES; PRETREATMENT; APOPTOSIS; CELLS;
D O I
10.1007/s00253-025-13409-1
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Lignin, the most abundant renewable source of aromatic compounds on earth, remains underexploited in traditional biorefining. Fraxetin, a naturally occurring flavonoid, has garnered considerable attention in the scientific community due to its diverse and potent biological activities such as antimicrobial, anticancer, antioxidant, anti-inflammatory, and neurological protective actions. To enhance the green and value-added utilization of lignin, Saccharomyces cerevisiae was engineered as a cell factory to transform lignin derivatives to produce fraxetin. The expression of scopoletin 8-hydroxylase (S8H) and coumarin synthase (COSY) enabled S. cerevisiae to produce fraxetin from ferulic acid, one of the three principal monomers. The optimized fermentation strategies produced 19.1 mg/L fraxetin from ferulic acid by engineered S. cerevisiae. Additionally, the engineered cell factory achieved a fraxetin titer of 7.7 mg/L in lignin hydrolysate. This study successfully demonstrates the biotransformation of lignin monomers and lignin hydrolysate into fraxetin using a S. cerevisiae cell factory, thereby providing a viable strategy for the valorization of lignin.
引用
收藏
页数:14
相关论文
共 59 条
  • [1] Fraxetin attenuates disrupted behavioral and central neurochemical activity in a model of chronic unpredictable stress
    Ahmed, Zainab
    Tokhi, Ahmed
    Arif, Mehreen
    Rehman, Naeem Ur
    Sheibani, Vahid
    Rauf, Khalid
    Sewell, Robert D. E.
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [2] Biosynthesis of fraxetin from three different substrates using engineered Escherichia coli
    An, Seung Hoon
    Choi, Gyu-Sik
    Ahn, Joong-Hoon
    [J]. APPLIED BIOLOGICAL CHEMISTRY, 2020, 63 (01)
  • [3] Advanced Biotechnology: Metabolically Engineered Cells for the Bio-Based Production of Chemicals and Fuels, Materials, and Health-Care Products
    Becker, Judith
    Wittmann, Christoph
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2015, 54 (11) : 3328 - 3350
  • [4] Heterologous production of the epoxycarotenoid violaxanthin in Saccharomyces cerevisiae
    Cataldo, Vicente F.
    Arenas, Natalia
    Salgado, Valeria
    Camilo, Conrado
    Ibanez, Francisco
    Agosin, Eduardo
    [J]. METABOLIC ENGINEERING, 2020, 59 (59) : 53 - 63
  • [5] Fraxetin alleviates microglia-mediated neuroinflammation after ischemic stroke
    Deng, Shi-Ji
    Ge, Jian-Wei
    Xia, Sheng-Nan
    Zou, Xin-Xin
    Bao, Xin-Yu
    Gu, Yue
    Xu, Yun
    Meng, Hai-Lan
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (08)
  • [6] Biosynthesis of catharanthine in engineered Pichia pastoris
    Gao, Jucan
    Zuo, Yimeng
    Xiao, Feng
    Wang, Yiling
    Li, Dongfang
    Xu, Junhao
    Ye, Cuifang
    Feng, Linjuan
    Jiang, Leijie
    Liu, Tengfei
    Gao, Di
    Ma, Bin
    Huang, Lei
    Xu, Zhinan
    Lian, Jiazhang
    [J]. NATURE SYNTHESIS, 2023, 2 (03): : 231 - +
  • [7] Iterative integration of multiple-copy pathway genes in Yarrowia lipolytica for heterologous β-carotene production
    Gao, Shuliang
    Tong, Yangyang
    Zhu, Li
    Ge, Mei
    Zhang, Yian
    Chen, Daijie
    Jiang, Yu
    Yang, Sheng
    [J]. METABOLIC ENGINEERING, 2017, 41 : 192 - 201
  • [8] Gibson DG, 2009, NAT METHODS, V6, P343, DOI [10.1038/NMETH.1318, 10.1038/nmeth.1318]
  • [9] Gietz RD, 2014, METHODS MOL BIOL, V1163, P33, DOI 10.1007/978-1-4939-0799-1_4
  • [10] Health benefits of fraxetin: From chemistry to medicine
    Ha, Nguyen Manh
    Son, Ninh The
    [J]. ARCHIV DER PHARMAZIE, 2024, 357 (07)